Gerald D Hurst

Title: Gerald D Hurst: Innovator in Oligonucleotide Crosslinking

Introduction

Gerald D Hurst is an accomplished inventor based in The Woodlands, TX. He is known for his significant contributions to the field of oligonucleotide research, holding two patents that demonstrate innovative approaches to crosslinking strategies in nucleic acids.

Latest Patents

Hurst's latest patents focus on the development of crosslinking oligonucleotides. One patent discusses oligonucleotides (ODNs) that contain a sequence complementary to a target in single-stranded RNA or single/double-stranded DNA along with an alkylating function. This function allows the ODNs to chemically modify the target sequence after hybridization. The ODNs are designed to target single-stranded RNA, such as messenger RNA, and contain complementary sequences in the Watson-Crick format. For double-stranded DNA, the ODNs feature at least two alkylating functions that engage with the target sequence either in the Hoogsteen or reverse Hoogsteen manner, thus allowing for alkylation of both strands. Additionally, Hurst has developed a third class of ODNs that have approximately 26 nucleotide units in a continuous sequence, which bind to double-stranded DNA and include a covalently attached alkylating function. Notably, alkylation with this class of ODNs occurs in the presence of a recombinase enzyme, showcasing a sophisticated mechanism for genetic modifications.

His second patent presents a novel concept involving substituted nucleotide bases characterized by a crosslinking arm, which enables crosslinking between specific sites on adjoining strands of oligonucleotides or oligodeoxynucleotides. This innovation opens new avenues for diagnostic and therapeutic applications, where the crosslinking agents can be utilized effectively in various biomedical scenarios.

Career Highlights

Gerald D Hurst is associated with Epoch Pharmaceuticals, Inc., where his research efforts are focused on pioneering advancements in the pharmaceutical applications of oligonucleotides. His innovative work in the area of nucleic acid technology has positioned him as a key figure in this specialized field.

Collaborations

Hurst has collaborated with notable coworkers, including Charles R Petrie and Rich B Meyer, Jr. Together, they have contributed to advancements in oligonucleotide research, enhancing the understanding and utilization of crosslinking agents for therapeutic purposes.

Conclusion

Gerald D Hurst's work represents a significant advancement in the application of oligonucleotides, particularly in their use for crosslinking specific target sequences. His inventions not only contribute to the scientific community but also pave the way for potential therapeutic innovations in gene modification and treatment strategies.